Overview

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Status:
Not yet recruiting

Trial end date:
2024-09-30

Target enrollment:

Participant gender:

Summary

This is a phase 2/3, multicenter, randomized, open, positive-controlled study of patients with advanced non-small cell lung cancer whose disease has progressed after prior anti-PD-(L)1 therapy. Subjects should have documented progressive disease during prior treatment with first- or second-line PD-(L)1 and platinum-containing dual-agent chemotherapy.Subjects will be randomized to three treatment groups in a 4:1:4 ratio. Treatment Group 1: KN046 5mg/kg every 2 weeks + lenvatinib recommended for phase III dose (RP3D) every day. Treatment Group 2: lenvatinib RP3D every day . Control group: Docetaxel 75mg/m2 every 3 weeks .

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Treatments:

Docetaxel
Lenvatinib